Personalised Cancer Therapeutics Lab


Oral Squamous Cell Carcinoma in Young Patients Show Higher Rates of EGFR Amplification: Implications for Novel Personalized Therapy
Satgunaseelan, L.; Porazinski, S.; Strbenac, D.; Istadi, A.; Willet, C.; Chew, T.; Sadsad, R.; Palme, C. E.; Lee, J. H.; Boyer, M.; Yang, J. Y. H.; Clark, J. R.; Pajic, M.; Gupta, R.
Frontiers in Oncology 11:750852, 2021
The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
Parkin, A.; Man, J.; Chou, A.; Nagrial, A. M.; Samra, J.; Gill, A. J.; Timpson, P.; Pajic, M.
Diseases 6(4):103, 2018
Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors
Hoque, M.; Abbassi, R. H.; Froio, D.; Man, J.; Johns, T. G.; Stringer, B. W.; Day, B. W.; Pajic, M.; Kassiou, M.; Munoz, L.
Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
Dreyer, S. B.; Upstill-Goddard, R.; Paulus-Hock, V.; Paris, C.; Lampraki, E. M.; Dray, E.; Serrels, B.; Caligiuri, G.; Rebus, S.; Plenker, D.; Galluzzo, Z.; Brunton, H.; Cunningham, R.; Tesson, M.; Nourse, C.; Bailey, U. M.; Jones, M.; Moran-Jones, K.; Wright, D. W.; Duthie, F.; Oien, K.; Evers, L.; McKay, C. J.; McGregor, G. A.; Gulati, A.; Brough, R.; Bajrami, I.; Pettitt, S.; Dziubinski, M. L.; Candido, J.; Balkwill, F.; Barry, S. T.; Grutzmann, R.; Rahib, L.; Glasgow Precision Oncology, Laboratory; Australian Pancreatic Cancer Genome, Initiative; Johns, A.; Pajic, M.; Froeling, F. E. M.; Beer, P.; Musgrove, E. A.; Petersen, G. M.; Ashworth, A.; Frame, M. C.; Crawford, H. C.; Simeone, D. M.; Lord, C.; Mukhopadhyay, D.; Pilarsky, C.; Tuveson, D. A.; Cooke, S. L.; Jamieson, N. B.; Morton, J. P.; Sansom, O. J.; Bailey, P. J.; Biankin, A. V.; Chang, D. K.
GASTROENTEROLOGY 160(1):362-377 e13, 2021
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer
Brunton, H.; Caligiuri, G.; Cunningham, R.; Upstill-Goddard, R.; Bailey, U. M.; Garner, I. M.; Nourse, C.; Dreyer, S.; Jones, M.; Moran-Jones, K.; Wright, D. W.; Paulus-Hock, V.; Nixon, C.; Thomson, G.; Jamieson, N. B.; McGregor, G. A.; Evers, L.; McKay, C. J.; Gulati, A.; Brough, R.; Bajrami, I.; Pettitt, S. J.; Dziubinski, M. L.; Barry, S. T.; Grutzmann, R.; Brown, R.; Curry, E.; Glasgow Precision Oncology, Laboratory; Australian Pancreatic Cancer Genome, Initiative; Pajic, M.; Musgrove, E. A.; Petersen, G. M.; Shanks, E.; Ashworth, A.; Crawford, H. C.; Simeone, D. M.; Froeling, F. E. M.; Lord, C. J.; Mukhopadhyay, D.; Pilarsky, C.; Grimmond, S. E.; Morton, J. P.; Sansom, O. J.; Chang, D. K.; Bailey, P. J.; Biankin, A. V.
Cell Reports 31(6):107625, 2020
Breaking the cycle: Targeting of NDRG1 to inhibit bi-directional oncogenic cross-talk between pancreatic cancer and stroma
Geleta, B.; Park, K. C.; Jansson, P. J.; Sahni, S.; Maleki, S.; Xu, Z.; Murakami, T.; Pajic, M.; Apte, M. V.; Richardson, D. R.; Kovacevic, Z.
FASEB JOURNAL 35(2):e21347, 2021
Pan-cancer analysis of whole genomes
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium.
NATURE 578(7793):82-93, 2020
Fats and Mets, KRAS-Driven Lipid Dysregulation Affects Metastatic Potential in Pancreatic Cancer
Man, J.; Pajic, M.; Joshua, A. M.
CANCER RESEARCH 80(22):4886-4887, 2020
GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
Martinelli, P.; Carrillo-de Santa Pau, E.; Cox, T.; Sainz, B., Jr.; Dusetti, N.; Greenhalf, W.; Rinaldi, L.; Costello, E.; Ghaneh, P.; Malats, N.; Buchler, M.; Pajic, M.; Biankin, A. V.; Iovanna, J.; Neoptolemos, J.; Real, F. X.
GUT 66(9):1665-1676, 2017
miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense
Pajic, M.; Froio, D.; Daly, S.; Doculara, L.; Millar, E.; Graham, P. H.; Drury, A.; Steinmann, A.; de Bock, C. E.; Boulghourjian, A.; Zaratzian, A.; Carroll, S.; Toohey, J.; O'Toole, S. A.; Harris, A. L.; Buffa, F. M.; Gee, H. E.; Hollway, G. E.; Molloy, T. J.
CANCER RESEARCH 78(2):501-515, 2018
Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes
Pajic, M.; Scarlett, C.J.; Chang, D.K.; Sutherland, R.L.; Biankin, A.V.
HUMAN GENETICS 130(1):93-101, 2011
Effective modulation of stromal signaling through ROCK inhibition: Is it all in the timing?
Chin, V.; Vennin, C.; Timpson, P.; Pajic, M.
Targeting the complexity of Src signalling in the tumour microenvironment of pancreatic cancer: from mechanism to therapy
Parkin, A.; Man, J.; Timpson, P.; Pajic, M.
FEBS Journal 286(18):3510-3539, 2019
Sex differences in oncogenic mutational processes
Li, C. H.; Prokopec, S. D.; Sun, R. X.; Yousif, F.; Schmitz, N.; PCAWG Tumour Subtypes, .; Clinical Translation, .; Boutros, P. C.; PCAWG Consortium, .
Nature Communications 11(1):4330, 2020
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
Bailey, M. H.; Meyerson, W. U.; Dursi, L. J.; Wang, L. B.; Dong, G.; Liang, W. W.; Weerasinghe, A.; Li, S.; Kelso, S.; MC3 Working Group, .; PCAWG novel somatic mutation calling methods working group, .; Saksena, G.; Ellrott, K.; Wendl, M. C.; Wheeler, D. A.; Getz, G.; Simpson, J. T.; Gerstein, M. B.; Ding, L.; PCAWG Consortium, .
Nature Communications 11(1):4748, 2020
Hypermutation in pancreatic cancer
Humphris, J. L.; Patch, A. M.; Nones, K.; Bailey, P. J.; Johns, A. L.; McKay, S.; Chang, D. K.; Miller, D. K.; Pajic, M.; Kassahn, K. S.; Quinn, M. C.; Bruxner, T. J.; Christ, A. N.; Harliwong, I.; Idrisoglu, S.; Manning, S.; Nourse, C.; Nourbakhsh, E.; Stone, A.; Wilson, P. J.; Anderson, M.; Fink, J. L.; Holmes, O.; Kazakoff, S.; Leonard, C.; Newell, F.; Waddell, N.; Wood, S.; Mead, R. S.; Xu, Q.; Wu, J.; Pinese, M.; Cowley, M. J.; Jones, M. D.; Nagrial, A. M.; Chin, V. T.; Chantrill, L. A.; Mawson, A.; Chou, A.; Scarlett, C. J.; Pinho, A. V.; Rooman, I.; Giry-Laterriere, M.; Samra, J. S.; Kench, J. G.; Merrett, N. D.; Toon, C. W.; Epari, K.; Nguyen, N. Q.; Barbour, A.; Zeps, N.; Jamieson, N. B.; McKay, C. J.; Carter, C. R.; Dickson, E. J.; Graham, J. S.; Duthie, F.; Oien, K.; Hair, J.; Morton, J. P.; Sansom, O. J.; Grutzmann, R.; Hruban, R. H.; Maitra, A.; Iacobuzio-Donahue, C. A.; Schulick, R. D.; Wolfgang, C. L.; Morgan, R. A.; Lawlor, R. T.; Rusev, B.; Corbo, V.; Salvia, R.; Cataldo, I.; Tortora, G.; Tempero, M. A.; Australian Pancreatic Cancer Genome Initiative, .; Hofmann, O.; Eshleman, J. R.; Pilarsky, C.; Scarpa, A.; Musgrove, E. A.; Gill, A. J.; Pearson, J. V.; Grimmond, S. M.; Waddell, N.; Biankin, A. V.
GASTROENTEROLOGY 152(1):68-74 e2, 2017
Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma
Kryza, T.; Khan, T.; Puttick, S.; Li, C.; Sokolowski, K. A.; Tse, B. W.; Cuda, T.; Lyons, N.; Gough, M.; Yin, J.; Parkin, A.; Deryugina, E. I.; Quigley, J. P.; Law, R. H. P.; Whisstock, J. C.; Riddell, A. D.; Barbour, A. P.; Wyld, D. K.; Thomas, P. A.; Rose, S.; Snell, C. E.; Pajic, M.; He, Y.; Hooper, J. D.
Theranostics 10(9):4116-4133, 2020
Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
Kryza, T.; Khan, T.; Lovell, S.; Harrington, B. S.; Yin, J.; Porazinski, S.; Pajic, M.; Koistinen, H.; Rantala, J. K.; Dreyer, T.; Magdolen, V.; Reuning, U.; He, Y.; Tate, E. W.; Hooper, J. D.
Nature Chemical Biology 17(7):776-783, 2021
Precision oncology in surgery: Patient selection for operable pancreatic cancer
Dreyer, S. B.; Pinese, M.; Jamieson, N. B.; Scarlett, C. J.; Colvin, E. K.; Pajic, M.; Johns, A. L.; Humphris, J. L.; Wu, J.; Cowley, M. J.; Chou, A.; Nagrial, A. M.; Chantrill, L.; Chin, V. T.; Jones, M. D.; Moran-Jones, K.; Carter, C. R.; Dickson, E. J.; Samra, J. S.; Merrett, N. D.; Gill, A. J.; Kench, J. G.; Duthie, F.; Miller, D. K.; Cooke, S.; Aust, D.; Knosel, T.; Rummele, P.; Grutzmann, R.; Pilarsky, C.; Nguyen, N. Q.; Musgrove, E. A.; Bailey, P. J.; McKay, C. J.; Biankin, A. V.; Chang, D. K.; Australian Pancreatic Cancer Genome, Initiative; Glasgow Precision Oncology, Laboratory
ANNALS OF SURGERY 272(2):366-376, 2020
PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines
Wang, K.; Huynh, N.; Wang, X.; Pajic, M.; Parkin, A.; Man, J.; Baldwin, G. S.; Nikfarjam, M.; He, H.
American Journal of Translational Research 11(6):3353-3364, 2019
Selected alkylating agents can overcome drug tolerance of G0-like tumor cells and eradicate BRCA1-deficient mammary tumors in mice
Pajic, M.; Blatter, S.; Guyader, C.; Gonggrijp, M.; Kersbergen, A.; Kucukosmanoglu, A.; Sol, W.; Drost, R.; Jonkers, J.; Borst, P.; Rottenberg, S.
CLINICAL CANCER RESEARCH 23(22):7020-7033, 2017
Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
Chou, A.; Froio, D.; Nagrial, A. M.; Parkin, A.; Murphy, K. J.; Chin, V. T.; Wohl, D.; Steinmann, A.; Stark, R.; Drury, A.; Walters, S. N.; Vennin, C.; Burgess, A.; Pinese, M.; Chantrill, L. A.; Cowley, M. J.; Molloy, T. J.; Waddell, N.; Johns, A.; Grimmond, S. M.; Chang, D. K.; Biankin, A. V.; Sansom, O. J.; Morton, J. P.; Grey, S. T.; Cox, T. R.; Turchini, J.; Samra, J.; Clarke, S. J.; Timpson, P.; Gill, A. J.; Pajic, M.
GUT 67(12):2142-2155, 2018